Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds

13G Filing: Highbridge Capital Management and Novelion Therapeutics Inc. (NVLN)

Published on May 1, 2017 at 4:40 pm by Insider Monkey Staff in Hedge Funds
<< Prev
Page 4 of 6
Next >>
See All

Page 4 of 6 – SEC Filing

(h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
(i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
(j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
(k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J),
please

specify the type of institution:_________________________
Item 4. OWNERSHIP.
(a) Amount beneficially owned:
As of the date hereof, Highbridge Capital Management, LLC, as the trading manager of Highbridge International LLC and Highbridge Tactical Credit & Convertibles Master Fund, L.P. (collectively, the “Highbridge Funds“), may be deemed to be the beneficial owner of the 1,000,000 Common Shares held by the Highbridge Funds.
(b) Percent of class:

The percentages
used herein and in the rest of this Schedule 13G are calculated based upon 18,558,072 Common Shares
reported to be outstanding in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2016 filed with the
Securities and Exchange Commission on March 30, 2017. Therefore, as of the date hereof, based on the Company’s outstanding
Common Shares, Highbridge Capital Management, LLC may be deemed to beneficially own approximately 5.39% of the outstanding Common
Shares of the Company.

The foregoing should not be construed in and of
itself as an admission by the Reporting Person as to beneficial ownership of the Common Shares held by the Highbridge Funds.
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote
0
(ii) Shared power to vote or to direct the vote
0
(iii) Sole power to dispose or to direct the disposition of
0

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)
<< Prev
Page 4 of 6
Next >>
See All

Related Insider Monkey Articles
13G Filing: Biotechnology Value Fund LP and Oncomed Pharmaceuticals Inc (OMED...13G Filing: Adage Capital Management and Audentes Therapeutics Inc (BOLD)
13G Filing: Soroban Capital Partners and Praxair Inc (PX)13G Filing: David Forster and Homeland Resources Ltd. (HMLA)
13G Filing: 683 Capital Partners and Innocoll Holdings PLC (INNL)13G Filing: Weiss Asset Management and KLR Energy Acquisition Corp (KLREU)